CE Ventures has joined a $55 million Series A funding round for US based biotech company Think Bioscience. CE Ventures is the venture capital arm of Crescent Enterprises, headquartered in the UAE. The round was oversubscribed and reflects strong investor confidence in next generation drug discovery platforms.
The funding round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors. Several new and returning investors also participated. The capital will help Think Bioscience advance its drug pipeline and expand its synthetic biology discovery platform.
A Strategic Investment in Advanced Biotech
CE-Ventures focuses on high impact, R&D driven businesses with global potential. This investment aligns with its strategy to support breakthrough science and asset light innovation models.
Key participants in the round include:
- Regeneron Ventures
- Innovation Endeavors
- Janus Henderson Investors
- MBX Capital
- YK Bioventures
- Returning early stage investors
The oversubscription highlights growing demand for solutions that address major gaps in modern medicine.
Think Bioscience and the Undruggable Challenge
Think Bioscience develops synthetic biology enabled platforms to design small molecule drugs. The company targets proteins long considered undruggable.
Many disease related proteins lack clear binding sites. Traditional drug discovery struggles to reach them. Think Bioscience uses high throughput functional surveys to uncover hidden pockets on proteins. These pockets allow chemists to design new therapies.
The platform enables:
- Discovery of novel protein binding sites
- Design of first in class small molecule drugs
- Expansion into difficult disease targets
This approach opens new paths for patients with limited treatment options.
Focus on Noonan Syndrome
Think Bioscience’s lead program targets Noonan syndrome. This is a rare genetic condition affecting about one in 2,500 births. Patients often face heart defects, lymphatic disorders, short stature, cognitive challenges, and chronic pain.
There are no approved therapies that address the root biology of Noonan syndrome. Think Bioscience aims to change that. Its program targets disease causing mutations directly.
Dr. Jerome Fox, Co Founder and CEO, stated that the program could help many patients live normal lives. The company plans to advance this program quickly with the new funding.
Why CE Ventures Joined the Round
Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises, highlighted the platform’s potential to expand what drug discovery can achieve. He emphasized the importance of supporting technologies that address high unmet medical needs.
Damir Illich, Manager of Life Sciences at CE Ventures, will join Think Bioscience’s board as an observer. He noted that the Noonan syndrome program shows how powerful the platform can be where no approved therapies exist.
Building Global Impact Through Science
The investment strengthens CE Ventures’ presence in global biotech. It also supports collaboration across science, capital, and policy. CE Ventures continues to convene experts through initiatives like its upcoming microbiome focused symposium in Dubai.
With this funding, Think Bioscience moves closer to delivering therapies once viewed as impossible. The partnership reflects a shared belief in science led innovation and long term patient impact.